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Abstract
Hyperandrogenism is characteristic of women with polycystic ovary syndrome (PCOS). Ovarian theca cells isolated from
PCOS follicles and maintained in long-term culture produce elevated levels of progestins and androgens compared to
normal theca cells. Augmented steroid production in PCOS theca cells is associated with changes in the expression of genes
for several steroidogenic enzymes, including CYP11A1, which encodes cytochrome P450 cholesterol side-chain cleavage.
Here, we further examined CYP11A1 gene expression, at both the transcriptional and post-transcriptional level in normal
and PCOS theca cells propagated in long-term culture utilizing quantitative RT-PCR, functional promoter analyses, and
mRNA degradation studies. The minimal element(s) that conferred increased basal and cAMP-dependent CYP11A1 promoter
function were determined. CYP11A1 mRNA half-life in normal and PCOS theca cells was compared. Results of these
cumulative studies showed that basal and forskolin stimulated steady state CYP11A1 mRNA abundance and CYP11A1
promoter activity were increased in PCOS theca cells. Deletion analysis of the CYP11A1 promoter demonstrated that
augmented promoter function in PCOS theca cells results from increased basal regulation conferred by a minimal sequence
between 2160 and 290 bp of the transcriptional start site. The transcription factor, nuclear factor 1C2, was observed to
regulate basal activity of this minimal CYP11A1 element. Examination of mRNA stability in normal and PCOS theca cells
demonstrated that CYP11A1 mRNA half-life increased .2-fold, from approximately 9.22+/21.62 h in normal cells, to
22.38+/20.92 h in PCOS cells. Forskolin treatment did not prolong CYP11A1 mRNA stability in either normal or PCOS theca
cells. The 59-UTR of CYP11A1 mRNA confers increased basal mRNA stability in PCOS cells. In conclusion, these studies show
that elevated steady state CYP11A1 mRNA abundance in PCOS cells results from increased transactivation of the CYP11A1
promoter and increased CYP11A1 mRNA stability.
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Introduction
PCOS is the most common cause of infertility in women [1] and
affects approximately 7% of women of reproductive age. PCOS
ovaries are characterized by the accumulation of small follicles 4–
7 mm in diameter, with hypertrophied theca interna layers.
Reproductive endocrine abnormalities in PCOS include amenor-
rhea or oligomenorrhea, infertility, hirsutism and acne resulting
from increased ovarian androgen production [2–6]. Theca cells
are recognized as one of the primary sources of excess androgen
biosynthesis in women with PCOS [7–10]. In response to
luteinizing hormone, theca cells express a variety of genes
encoding components of the steroidogenic pathway that are
necessary for androgen and progestin biosynthesis [11–13].
Steroidogenic acute regulatory protein (StAR) promotes the
translocation of cholesterol from the outer to the inner mitochon-
drial membrane [14,15], where cytochrome P450 side chain
cleavage enzyme, P450scc, converts cholesterol to pregnenolone,
the first step in steroid hormone synthesis [16,17]. The synthesis of
androgens is also contingent upon the expression of the
cytochrome P450 17a-hydroxylase (CYP17A1) gene, which
encodes a single cytochrome P450 (P450c17) with both 17a-
hydroxylase and C17, 20 lyase activities responsible for the
conversion of pregnenolone to 17a-hydroxypregnenolone, and
subsequently dehydroepiandrosterone (DHEA) [18].
Our previous studies demonstrated that both progesterone and
androgen production are persistently elevated in theca cells
isolated from the ovaries of women with PCOS, propagated for
successive population doublings in vitro [19,20]. This increase in
steroid production in PCOS theca cells is associated with
augmented expression of several steroidogenic enzymes, including
CYP11A1, CYP17A1, and 3b-hydroxysteroid dehydrogenase, type
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2 (HSD3B2) [19,21]. The underlying mechanism of this coordi-
nated upregulation is unknown. Investigation of CYP17 gene
expression in normal and PCOS theca cells has revealed that
increased CYP17 mRNA abundance results from both increased
transactivation of the promoter and augmented mRNA stability in
PCOS [22,23]. The transcription factor, NF-1C2, was found to
play an important role in increased basal CYP17A1 gene
expression in PCOS theca cells and adrenal H295 cells [24]. In
addition, the 59-untranslated (59UTR) region of CYP17 mRNA
was shown to confer increased mRNA half-life in PCOS theca
cells as compared to normal theca cells, thus increasing CYP17A1
expression in both of the above cases.
We previously reported that augmented CYP11A1 gene
expression also involves increased transactivation of the CYP11A
gene and promoter in PCOS theca cells [25]. In the present study,
we have examined the extent to which changes in transcriptional
and post-transcriptional regulation play a role in increased
CYP11A1 gene expression in PCOS theca cells. We have identified
the boundaries of the CYP11A1 promoter that confer increased
basal and cAMP-dependent expression in normal and PCOS
theca cells utilizing functional promoter analyses. Moreover, we
have identified the minimal element that confers increased basal
regulation in PCOS theca cells. We investigated the possibility that
the transcription factor, nuclear factor 1 (NF-1C2), which we had
reported to play a role in basal CYP17 gene expression in PCOS
theca cells, coordinately regulates basal CYP11A1 gene expression.
In this report, we also performed CYP11A1 mRNA half-life and
mRNA degradation studies, to determine the overall contribution
of increased CYP11A1 stability to increased gene expression in
PCOS theca cells.
Materials and Methods
Ethics Statement
Human theca interna tissue was obtained from follicles of
women undergoing hysterectomy for non-related purposes,
following informed consent under protocol that has been approved
by the Institutional Review Board (IRB) of the Human Subjects
Protection Office of the Pennsylvania State University College of
Medicine. Signed IRB approved consent was obtained prior to
surgery at the patient’s pre-operative visit. All surgeries were
performed for non-related gynecologic indications, most com-
monly for dysfunctional uterine bleeding and/or intrauterine
abnormalities such as endometrial hyperplasia or endometriosis.
Oophorectomy involving one or both ovaries, was discussed
individually with these women by their physicians, and was chosen
as a course of treatment in many cases by the patient to ameliorate
pelvic pain and/or menorrhagia.
Theca cell isolation and propagation
Fragments of ovaries were obtained from discarded ovarian
specimens from pathology gross room. Individual follicles were
dissected away from ovarian stroma, and dispersed with 0.05%
collagenase I, 0.05% collagenase IA, and 0.01% deoxyribonucle-
ase, in medium containing 10% fetal bovine serum (FBS), as
previously described [26]. The isolated follicles were size-selected
for diameters ranging from 3–5 mm so that theca cells derived
from follicles of similar size from normal and PCOS subjects could
be compared. Theca cells were cultured on fibronectin coated
dishes utilizing previously described ‘‘growth medium’’ (1:1
mixture of Dulbecco’s Eagles Medium (DME) and Hams F-12
medium, containing 5% FBS, 5% horse serum (HS), 2% UltroSer
G, 20 nM insulin, 20 nM selenium, 1 mM vitamin E, and
antibiotics) [27]. Sera and growth factors were obtained from
the following sources: FBS and DME/F12 (Irvine Scientific,
Irvine, CA): horse serum (Life Technologies, Grand Island, NY);
UltroSer G (Reactifs IBF, Villeneuve-la-Garenne, France): other
compounds were purchased from Sigma (St. Louis, MO). The cells
were grown in reduced oxygen tension (5% O2, 90% N2, and 5%
CO2) and given supplemental antioxidants (vitamin E and
selenium) to prevent oxidative damage [27]. The reduced oxygen
tension and concentrations of bovine (5%) and horse serum (5%)
and UltroSer (2%) in the ‘‘growth medium’’ described above, were
previously reported to be the most effective to grow human theca
cells for successive population doublings with maintenance of
inducible 17a-hydroxylase activity and steroidogenic function
[27,28].
The theca cell cultures utilized in these studies have been
described and functionally characterized previously [19,22,29,30].
Experiments comparing PCOS and normal theca were performed
utilizing 4th-passage (31–38 population doublings) theca cells
isolated from size-matched follicles. The use of 4th passage cells
allowed us to perform multiple experiments from the same patient
population, and were propagated from frozen stocks of second
passage cells in the media described above. For all studies, theca
cell cultures obtained from at least 5 independent normal and 5
independent PCOS patients were examined unless otherwise
specified. The passage conditions and split ratios for all normal
and PCOS cells were identical.
The PCOS and normal ovarian tissue came from age-matched
women, 38–40 years old. The diagnosis of PCOS was made
according to NIH consensus guidelines [31], which include
hyperandrogenemia, oligoovulation, polycystic ovaries, and the
exclusion of 21-hydroxylase deficiency (AM 17a-hydroxyproges-
terone), Cushings (elevated cortisol, and physical examination),
and hyperprolactinemia. All of the PCOS theca cell preparations
studied came from ovaries of women with fewer than six menses
per year and elevated serum total testosterone or bioavailable
testosterone levels, as previously described [19,32]. Each of the
PCOS ovaries contained multiple subcortical follicles of less than
10 mm in diameter. The control (normal) theca cell preparations
came from ovaries of fertile women with normal menstrual
histories, menstrual cycles of 21–35 days, and no clinical signs of
hyperandrogenism. Neither PCOS nor normal subjects were
receiving hormonal medications at the time of surgery. Indications
for surgery were dysfunctional uterine bleeding, endometrial
cancer, and/or pelvic pain.
CYP11A1 mRNA Quantitation
For quantitative real-time PCR, total RNA was isolated [19]
from theca cells that were grown to subconfluence, transferred into
serum-free medium, containing DMEM/F12 1.0 mg/mL BSA,
100 mg/mL transferrin, 20 nM insulin, 20 nM selenium, 1.0 mM
vitamin E and antibiotics, and treated as indicated. RNA (1 mg)
samples were then reverse transcribed using oligo (dT) and 200
units Stratascript Reverse Transcriptase (Stratagene, Cedar Creek,
TX). CYP11A1 mRNA abundance was determined by quantita-
tive Real-time PCR as previously described [29], using a gene
specific two-step PCR and carried out in triplicate for each cDNA
sample as well as a series of serial dilutions in a Mx3000P
Thermocycler (Stratagene, Cedar Creek, TX). For quantitation of
CYP11A1 (Fig. 1), we utilized the forward primer (59-GAGGGA-
GACGGGCACACA-39), the reverse primer (59-TGACA-
TAAACCGACTCCACGTT-39) and CYP11A1 specific probe
(59-TCCACCTTCACCATGTC CAGAAT-39). 18S ribosomal
and/or TATA-binding protein quantitated (TBP) mRNA abun-
dance was utilized for data normalization as noted. For
quantitation of TBP we utilized the forward primer (59- F-
Augmented CYP11A1 Expression in PCOS Theca Cells
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CACGGCACTGATTTTCAGTTCT-39), the reverse primer (59-
TCTTGCTGCCAGTCTGGACT-39) and TBP specific probe
(59- TGTGCACAGGAGCCAAGAGTGAAGA - 39). For quan-
titation of 18S we utilized primer and probe sets from Invitrogen.
For determination of mRNA half-life, theca cells maintained in
serum-free media for 24 h (time zero) were treated with 75 mM of
the transcription inhibitor 5, 6-dichloro-benzimidazole 1-b-D-
ribofuranoside (DRB) for 0 to 48 h. The rate of decay (k) was
assessed by measuring the amount of CYP11A1 mRNA at each
timepoint, over the amount at time zero, and determined by
nonlinear regression (Prism 5.0, GraphPad Software, San Diego,
CA). Half-life (t1/2) of transcripts/mRNA were calculated from the
k based on the equation, t1/2 = (ln 2)/k.
Construction of CYP11A1 promoter constructs
The 22327 and 21676 CYP11A1 LUC, containing 22327 or
21676/+49 bp of the 59-flanking sequence of the human
CYP11A1 promoter in pGL3-basic (Fig. 2A), have been previously
described [25,33]. Sequentially smaller fragments of the human
CYP11A1 gene promoter were generated by PCR amplification
using the following forward primers (2660 CYP11A1, 59-
cctgagctcCAGAGTGGAGCCTGACCA-39; 2160 CYP11A1, 59-
cctgagctcACGCTGCAGAAATTC CAG-39; 290 CYP11A1, 59-
cctgagctcTGCAGCAGGAG GAAGGA -39) and a reverse primer
corresponding to the pGL3-basic polylinker (59gccaagcttACTTA-
GATCGCA GATCTG-39). PCR product was amplified by 20
cycles of Expand Long Template PCR (Roche Diagnostics, IN),
and subcloned (Sac I/HindIII) into the pGL3 basic luciferase
vector (Promega). The deletion construct 21676D (2160/290)
was generated by PCR amplification of a sequence from 21676 to
2160, using the forward primers 21676 (59-gccggtacCTCAT-
CACCCTGCCGC TGC-39) and a 2160 reverse primer (59-
cctgagCTCTTCTCCAAAGGAC AGG-39), followed by Kpn I
and Sac I digestion and ligation into the 290 LUC construct
(Fig. 3A). For the deletion construct 21676D(1540/290) LUC,
oligonucleotides corresponding to 21676/21540 were annealed
and ligated into the290 LUC construct (Fig. 3A). For2160/290
TK LUC, oligonucleotides corresponding to 2160/290 were
annealed, digested with Sac I and Bgl II, and ligated into a
thymidine kinase (TK)-pGL3basic vector. The TK-pGL3basic
was constructed by subcloning the HSV TK promoter (BglII/
HindIII) from pRL-TK (Promega, Madison, WI) into pGL3-basic
(Fig. 3A). All constructs were confirmed by automated DNA
sequencing.
Construction of CYP11A1 UTR luciferase constructs
The 59-UTR CYP11A1/LUC construct was generated by
ligating annealed synthetic oligonucleotides corresponding to the
59-UTR of CYP11A1 mRNA into NcoI/HindIII sites of the
pGL3 control vector (Promega, Madison, WI) located upstream
(59) of the luciferase coding sequence. The construct was
confirmed by automated DNA sequencing.
Transient transfection of normal and PCOS theca cells
Human theca cells isolated from normal cycling women and
women with PCOS were transfected as previously described
[22,30,34] using the modified calcium phosphate method of
Graham and Van der Eb [34]. Theca cells were grown in growth
medium as described above. Sixteen hours prior to transfection,
the cells were sub-cultured at a 1:6 ratio in growth medium. One
hour prior to transfection, the cells were transferred into
transfection medium containing, DME high-glucose medium
containing 20 mM HEPES and 2% heat-inactivated calf serum
(Atlanta Biologicals, Atlanta, GA), and moved to a 3% CO2, 95%
Figure 1. Quantification of CYP11A1 mRNA abundance in
normal and PCOS theca cells. The time course of CYP11A1 mRNA
accumulation was examined in A) normal or B) PCOS theca cells treated
in serum free medium for 0, 4, 8, 16, 24, or 48 h in the presence and
absence of 20 mM forskolin. C) CYP11A1 mRNA accumulation in normal
and PCOS theca cells following 24 h treatment with and without 20 mM
forskolin serum free medium. CYP11A1 mRNA was measured using
quantitative real-time PCR as described in Materials and Methods. The
data presented in Panel A and Panel B are data obtained from two
normal and two PCOS patients, that are representative of data collected
from theca cells from 5 normal and 5 PCOS patients. The data presented
in Panel C are the results from independent analyses of theca cells
isolated from 5 normal and 5 PCOS women. CYP11A1 mRNA
accumulation was increased in PCOS theca cells as compared to
normal theca cells under both control (a, P,0.01) and forskolin-
stimulated conditions (b, P,0.01). Forskolin- treatment significantly
increased CYP11A1 mRNA accumulation in both normal and PCOS
theca cells (*, P,0.01).
doi:10.1371/journal.pone.0048963.g001
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ambient air, 37uC incubator. The cells were then transfected with
calcium phosphate precipitate containing 2 mg/dish of luciferase
plasmid and 0.1 mg/dish of an expression vector for b-galactosi-
dase, pSVb-gal (Promega, Madison, WI) and 20 mM CaCl2, per
30 mm well, as indicated. To increase transfection efficiency, 6 h
following transfection, the cells were glycerol shocked with a
solution containing 15% glycerol in 25 mM Hepes buffer
containing 140 mM NaCl and 0.5 mM Na2HPO4, and trans-
ferred into transfection media with and without 20 mM forskolin
for 48 h. The cells were then were harvested with trypsin, pelleted,
and resuspended in reporter lysis buffer (Promega). Luciferase
activity was determined with the Luciferase Assay System
(Promega) on a Sirius Luminometer (Zylux Corp., Oak Ridge,
TN). b-Galactosidase activity was measured by the chemilumi-
nescent assay Galacto-Light Plus (Tropix, Bedford, MA) and
utilized for normalization of transfection efficiency.
Figure 2. Deletion analysis of the CYP11A1 promoter in normal
and PCOS theca cells. A) Theca cells were transiently transfected
with pGL3 luciferase constructs containing22327,21676,2660,2160,
or 290 to +49 bp of the 59-flanking sequence of the CYP11A1 gene. All
constructs contain the endogenous TATA box and transcriptional start
site. B) Normal and PCOS theca cells were transiently transfected with
the above constructs described in Materials and Methods. Following
transfection, cells were cultured in transfection medium alone or with
forskolin (20 mM) for 48 h. Data are presented as relative luciferase
(LUC) activity that was normalized with b-galactosidase activity, and
represent the mean 6 SEM of independent experiments in five normal
and five PCOS theca cell cultures. CYP11A1 promoter activity was
increased in PCOS theca cells, under basal (a, P,0.01) and forskolin-
stimulated conditions (b, P,0.01), as compared to normal theca cells for
individual promoter constructs.
doi:10.1371/journal.pone.0048963.g002
Figure 3. Differential regulation of the minimal 2160/290 bp
CYP11A1 promoter region in normal and PCOS theca cells. A)
The full-length 21676 CYP11A1 construct, the 21676 construct that
lacks the 2160/290 bp region but retains sequences from 290 to
+49 bp (21676D2160/290), a 21676 construct containing the
sequence between 21676 to 21540 bp fused the minimal 290
CYP11A1 promoter construct (21676D21540/290) containing a
putative U-CRS element, and constructs containing the thymidine
kinase promoter alone (TK) or with the 2160/290 bp upstream of the
TK promoter (2160/290 TK). B) Normal and PCOS theca cells were
transiently transfected with the21676, 21676D2160/290,
21676D21540/290 promoter constructs as described in Materials
and Methods. Following transfection, cells were cultured in transfection
medium alone or with forskolin (20 mM) for 48 h C) Normal and PCOS
theca cells were transfected with promoter constructs containing either
TK, or with 2160/290 TK. Following transfection, cells were cultured in
transfection medium for 24 h. Data are presented as relative luciferase
(LUC) activity that was normalized with b-galactosidase activity, and
represent the mean 6 SEM of independent experiments in four normal
and four PCOS theca cell cultures. Both basal (a, P,0.01) and forskolin
(b, P,0.01) stimulated 21676 CYP11A1 promoter regulation is
increased in PCOS theca cells. In normal theca cells, 21676D21540/
290 CYP11A1 activity was significantly increased under basal conditions
(*, P,0.01), and forskolin-treatment (**, P,0.01) conditions, as
compared to the full-length 21676 CYP11A construct. In contrast, in
PCOS theca cells 21676D21540/290 CYP11A1 activity was significantly
increased under basal conditions (*, P,0.01), and forskolin stimulated
(**, P,0.01) conditions, as compared to the full-length 21676 CYP11A1
construct (Fig. 3B). These data demonstrate that 70 bp sequence
between 2160/290 bp of the start site of transcription of the CYP11A1
gene confers increased basal expression in PCOS theca cells. The U-CRS
element between 21676 to 1540 of the promoter confers basal and
cAMP-dependent regulation in both normal and PCOS theca cells.
doi:10.1371/journal.pone.0048963.g003
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Cytoplasmic Extract Preparation
Human theca cells were transferred into DMEM/F12 serum-
free medium containing 1.0 mg/mL BSA, 100 mg/mL transferrin,
20 nM insulin, 20 nM selenium, 1.0 mM vitamin E and antibiot-
ics, in the absence or presence of 10 mM forskolin. At 24 h, cells
were harvested with trypsin/EDTA and cytoplasmic extracts were
prepared in buffer containing 0.1% NP-40, 20 mM HEPES
(pH 7.9), 20 mM sodium chloride, 1 mM dithithreitol, 0.5 mM
PMSF, 0.2 mM EDTA, 2 mg/mL leupeptin, 1 mM benzamidine,
1 mM sodium orthovanadate, and 20 mM sodium fluoride to
inhibit protein phosphatases and proteases, as previously reported
[23]. Protein concentrations of cytoplasmic extracts were deter-
mined by BCA protein assay [23].
In vitro degradation of CYP11A1 mRNA
In vitro mRNA decay reactions were performed as previously
described [23,35]. Various lengths of the CYP11A1 cDNA were
generated by PCR amplification of a pBS-CYP11A1 plasmid
containing the full-length (1.86 kbp) CYP11A1 cDNA. The PCR
products contained a T7 promoter site and were used to synthesize
biotinylated CYP11A1 transcript in the MAXI script kit (Ambion,
Austin, TX). Reactions included 0.3 mg of cytoplasmic extract and
approximately 10 ng of biotinylated transcript in RNA degrada-
tion buffer comprised of 0.6 U recombinant RNAsin (Promega).
Components were combined on ice, mixed, and incubated at
37uC. For comparison of decay rates for transcripts of different
length, equamolar amounts of biotinylated RNA were included in
the reactions. At each timepoint from 0–60 min, 10 ml of the
reaction was removed and immediately precipitated in cold 70%
ethanol containing Glycoblue co-precipitant (Ambion, Austin,
TX). Following resuspension, the reactions were separated on a
1.5% agarose/formaldehyde gel and transferred to nylon mem-
brane. Biotinylated RNA was detected using the Bright Star
BioDetect kit (Ambion, Austin, TX) and quantitated using a
GeneGnome bioimager and GeneSnap v6.03 and GeneTools
v3.03 (Syngene Bioimaging, Cambridge, UK)
Statistical Analysis
Data are presented and described in the text as the mean 6
SEM from transfections or mRNA decay analysis (t1/2) performed
in triplicate in 5 independent normal and 5 independent PCOS
theca cells cultures unless otherwise noted. The results from QRT-
PCR, mRNA decay analysis (t1/2), and transfection analysis were
collected from individual patients and one-way ANOVA was
performed using Prism 3.0c (GraphPad Software, San Diego, CA).
P values were determined by the Tukey method for multiple
comparisons when significant differences were indicated by one-
way ANOVA.
Results
Comparison of steady state of CYP11A1 mRNA
abundance in theca cells from normal cycling and PCOS
women
Quantitative real-time PCR was utilized to examine the time
course of CYP11A1 mRNA in theca cells isolated from normal
and PCOS patients. Cells were grown until subconfluent in growth
medium then transferred into serum-free medium, and treated for
4, 8, 16, 24, or 48 h in the presence and absence of 20 mM
forskolin. At time zero prior to treatment, and the end of each time
point, the plates of cells were flash frozen, cells were harvested,
RNA was prepared, and CYP11A1 mRNA abundance was
quantified as described in Materials and Methods. As shown in
Figs. 1A–B, CYP11A1 mRNA can be measured at time zero in
both normal and PCOS theca cells and appears to be increased in
PCOS theca cells in the absence of treatment. As shown in Fig. 1B,
increased steady state CYP11A1 mRNA can be observed at 4–8 h
in normal and PCOS theca cells, under both basal and forskolin-
stimulated conditions. Under basal conditions, the amount of
CYP11A1 mRNA accumulation was similar following 8–48 h in
serum-free medium. Maximal induction of CYP11A1 mRNA was
achieved following 24 h treatment with forskolin in both normal
and PCOS theca cells (Figs. 1A–1B).
To compare steady state levels of CYP11A1 mRNA in normal
and PCOS theca cells, CYP11A1 mRNA abundance was
examined in normal and PCOS theca cells that had been grown
until subconfluent and transferred into serum-free medium with
and without 20 mM forskolin for 24 h. Following treatment, total
mRNA was harvested and CYP11A1 mRNA was quantitated
using real-time PCR as described in Materials and Methods. As
shown in Fig. 1B, CYP11A1 mRNA abundance is ,2–2.5-fold
higher in PCOS theca cells as compared to normal cells, under
both basal (a, P,0.01) and forskolin-stimulated (b, P,0.01)
conditions (Fig. 1B). Forskolin- treatment significantly increased
CYP11A1 mRNA accumulation in both normal and PCOS theca
cells (*, P,0.01). These data are in agreement with our previously
published Northern analysis and qRT-PCR indicating that PCOS
theca cells contain elevated steady state CYP11A1 mRNA levels
[19,25].
Deletion analysis of the CYP11A promoter
Previous examination of the human CYP11A1 promoter
function in theca cells indicated that sequences within 21676 bp
of the start site of transcription conferred transcriptional activity
and increased promoter function in PCOS [25]. To examine the
regions involved in increased promoter regulation in PCOS theca
cells, a series of promoter constructs containing successive
deletions of the 59-flanking sequence of the human CYP11A1 gene
were generated. Luciferase constructs containing 22327, 21676,
2660, 2160, or 290 to +49 bp of the CYP11A1 promoter were
transiently transfected into theca cells isolated from normal cycling
women and women with PCOS (Fig. 2A). In order to examine the
regions of the CYP11A1 promoter involved in basal, as well as
cAMP-dependent regulation, the cells were cultured in the
absence (basal) or presence of 20 mM forskolin for 48 h.
Comparison of CYP11A1 promoter function in normal and
PCOS theca cells showed that under both basal (a, P,0.01) and
forskolin-stimulated (b, P,0.01) conditions, 22327, 21676,
2660, and 2160 CYP1A1 LUC activity was increased approxi-
mately 2-fold in PCOS theca cells, as compared to normal theca
cells (Fig. 2B). In contrast, 290 CYP11A1 promoter function was
not different in normal and PCOS. A significant reduction in basal
and cAMP- dependent CYP11A1 promoter function was observed
following exclusion of sequences upstream of 21676 bp, and
2660 bp of the start site of transcriptions as well as 290 bp, in
both normal and PCOS cells. These data suggest the presence of
regulatory regions within 22327 to 2660 bp, as well as 2160 to
290 bp that contribute CYP11A1 promoter regulation in normal
and PCOS theca cells.
Treatment with forskolin resulted in significant increases in
promoter function for both the 22327 and 21676 CYP11A1
constructs (*, P,0.01). Whereas, deletion of sequence 59 of
2660 bp significantly reduced forskolin-induction of CYP11A
promoter constructs, indicating that sequences between 21676
and 2660 bp are required for cAMP-dependent regulation in
both normal and PCOS theca cells (Fig. 2B). The robust increase
in basal and cAMP-dependent reporter activity observed in
Augmented CYP11A1 Expression in PCOS Theca Cells
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following transfection of the 22327 bp and 21676 bp constructs,
most likely is the result of regulation through a previously
described U-CRS response elements, TCAAGGTCA located
between 21640 to 21553 bp, and 21931 to 21822 of the
CYP11A promoter which has SF-1 and CRE like binding sites, and
thus confers basal and cAMP-dependent regulation. Removal of
sequences upstream of 2660 bp resulted in a similar 2- to 3- fold
reduction in basal and forskolin-stimulated CYP11A1 promoter
function in both normal and PCOS cells.
2660 and 2160 CYP11A1 promoter function was increased 2-
fold in PCOS theca cells as compared in normal cells (a, P,0.01).
Both of these shorter CYP11A1 promoter constructs lacked cAMP
responsiveness. Deletion of sequences between 2160 to 290 bp,
reduced basal promoter function and ablated CYP11A1 promoter
function in both cell types. Together, these data suggest that
increased CYP11A1 promoter function in PCOS theca cells results
primarily from augmented basal regulation of an element within
the general boundaries of 2160 bp to 290 bp of the start site of
transcription of the CYP11A1 gene (Fig. 2B).
Increased CYP11A1 promoter regulation in PCOS theca
cells
To determine whether the sequence between 2160 to 290 bp
of CYP11A1 promoter are necessary for increased basal regulation
in PCOS theca cells, we constructed 21676 CYP11A1 promoter
constructs in which sequences between 2160 to 290 bp (21676
D2160/290) were deleted (Fig. 3A). In addition, to determine the
extent to which the putative U-CRS consensus element confers
both basal and cAMP dependent regulation in normal and PCOS
theca cells, we constructed a CYP11A1 reporter construct
containing the sequence between 21676 to 21540 bp fused to
the minimal 290 CYP11A1 promoter construct (21676D21540/
290). Both of these constructs were compared to the full-length
21676 CYP11A1 promoter construct following transient transfec-
tion analysis under basal and forskolin (20 mM) stimulated
conditions (Fig. 3B).
Compared to the full-length 21676 CYP11A1 promoter, the
function of 21676D2160/290 was significantly reduced in both
normal and PCOS theca cells under both basal (*, P,0.01) and
forskolin-stimulated conditions (**, P,0.01). In contrast to the
21676 promoter, whose function is .2-fold higher in PCOS
theca cells, there was no difference in 21676 D2160/290
promoter function in normal and PCOS cells (Fig. 3B). Given that
the deletion of 2160/290 bp reduces promoter function in both
normal and PCOS theca cells, and that lower promoter function
was also observed in the serial deletion of sequences from 2160 to
290, it is likely that basal regulatory sequences are found within
this region that confer increased regulation in PCOS theca cells.
Transient transfection analysis of the 21676D21540/290
CYP11A1 construct in normal and PCOS theca cells resulted in
almost identical increases in basal and forskolin-stimulated
luciferase activity (Fig. 3B), which were significantly higher than
that observed with the full length 21676 CYP11A1 construct. In
both normal and PCOS theca cells, forskolin stimulated
21676D21540/290 CYP11A1 reporter activity increased over
two-fold (c, P,0.01) compared to basal, non-stimulated values.
These data confirm those in the literature. demonstrating that the
U-CRS element between 21640 to 21553 bp of the promoter
confers basal and cAMP-dependent regulation in both normal and
PCOS theca cells. In normal theca cells, 21676D21540/290
CYP11A1 activity was significantly increased under basal condi-
tions .5-fold (*, P,0.01), and .7-fold following forskolin-
treatment (**, P,0.01) conditions, as compared to the full-length
21676 CYP11A construct (Fig. 3B). In contrast, in PCOS theca
cells 21676D21540/290 CYP11A1 activity was significantly
increased under basal conditions .2-fold (*, P,0.01) and .3-
fold following forskolin-treatment (**, P,0.01) conditions, as
compared to the full-length 21676 CYP11A construct (Fig. 3B).
These data suggest that sequences between 21540 and 290 bp of
the CYP11A1 promoter may confer differential regulation in
normal and PCOS theca cells.
To determine if the 2160/290 region of the CYP11A1
promoter confers increased activity in PCOS theca cells, we
transfected normal and PCOS theca cells with luciferase reporter
constructs containing the 2160/290 bp region fused to a
heterologous thymidine kinase promoter (Fig. 3A) or a luciferase
construct containing the empty TK promoter (TK). As shown in
Figure 3C, transfection of the empty luciferase construct, TK,
resulted in low but measureable levels of luciferase activity in
normal and PCOS theca cells, which were not significantly
different. Transfection of normal theca cells with the 2160/
290 bp region of the CYP11A1 promoter fused upstream of the
minimal thymidine kinase promoter (2160/290 TK) resulted in a
,2-fold increase in luciferase activity as compared to the empty
TK construct, which was not statistically significant. Transfection
of the 2160/290 TK construct in PCOS cells resulted in a .4-
fold increase compared to the empty TK construct (a, P,0.01),
and was increased 2-fold as compared to normal theca cells (*,
P,0.01). These data demonstrate that sequences within 2160 to
290 bp of the CYP11A promoter are necessary for increased
CYP11A1 promoter function in PCOS theca cells and contribute
to increased basal regulation.
NF-1C2 regulation of the CYP11A1 promoter
In studies examining the basis for increased CYP17 gene
expression in normal and PCOS theca cells, we previously
reported that a16 bp element between 2180 tp 2144 bp of the
CYP17 promoter that confers increased basal regulation in PCOS
theca cells. We demonstrated that transcription factor NF-1C2,
had the capacity to bind to this 16 bp minimal element and inhibit
(i.e., repress) the CYP17A1 promoter. Moreover, we reported that
NF-1C2 protein levels were reduced in PCOS theca cells,
suggesting that a decrease in NF-1 repression may be involved
in increased CYP17A1 gene expression in PCOS theca cells.
Examination of the 2160/290 bp CYP11A1 minimal element
suggests sequence similarity with the bipartite recognition
sequence ((C/T)TGGC(N)6CC(N)3) for NF-1 [36,37]. To examine
the possibility that NF-1C2 coordinately regulates CYP11A1 gene
expression in a manner similar to the CYP17A1 promoter, we
performed studies to examine the effect of a human NF-1C2
pcDNA plasmid or an empty pcDNA plasmid on the full length
21676 CYP11A1 promoter construct in normal and PCOS theca
cells. Following transfection, the cells were treated with and
without 20 mM forskolin. As shown as a comparison in Fig. 4A, co-
transfection with empty pcDNA plasmid alone had no effect on
21676 CYP11A1/LUC promoter function, and both basal and
forskolin-stimulated reporter function remained significantly aug-
mented in PCOS theca cells, as compared to normal theca cells (a,
b, P,0.01). In contrast to empty pcDNA plasmid, co-transfection
with NF-1C2 plasmid markedly inhibited basal and forskolin-
stimulated 21676 CYP11A1 promoter function in normal and
PCOS theca cells. In PCOS theca cells, basal promoter function
was significantly inhibited (b, P,0.01), and NF-1C2 co-transfec-
tion of PCOS cells, inhibited CYP11A1 promoter activity (Fig. 4A).
These data show that overexpression NF-1C in PCOS theca cells
has the ability to decrease CYP11A1 transcription, and suggest that
the previously reported increase in NF-1C levels observed in
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normal theca cells contribute to lowered levels of CYP11A1
expression which are phenotypic of the normal cycling ovary.
To identify sequences of the CYP11A1 promoter that confer NF-
1C2 regulation, theca cells were transfected with pGL3 constructs
containing 21676, 2160, or 290 to +49 bp of the 59-flanking
sequence of the CYP11A1 gene with the empty pcDNA plasmid or
NF-1C2 plasmid. In these experiments, we examined differences
in basal expression in the absence of forskolin, because basal
CYP17A1 and CYP11A1 promoter regulation are both conferred
by basal elements in PCOS theca cells. As shown in Fig. 4B, co-
transfection with pcDNA, or NF-1C2 has no effect on pGL3 or
290/LUC activity in PCOS theca cells. Both 21676 and 2160
CYP11A1/LUC promoter function are increased in theca cells
following pcDNA co-transfection (a, P,0.01), and NF-1C2
significantly (b, P,0.01) inhibits both of these activities in excess
of 50–75% (Fig. 4B), further suggesting that sequences between
2160 to 290 of the start site of transcription of the CYP11A1
promoter may confer NF-1C2 repression. To test this possibility,
we transfected PCOS theca cells with the CYP11A1 promoter
construct containing the 2160 to 290 sequence, 2160/290 TK
(see Fig. 4C) and the empty control TK constructs with the
pcDNA plasmid expressing NF-1C2 or the empty pcDNA
plasmid. Following transfection the cells were cultured in serum
free medium for 24 h. These experiments demonstrate that NF-
1C2 inhibits both basal and forskolin stimulated CYP11A1
promoter function in normal and PCOS theca cells. Moreover,
sequences between 2160/290 bp of the CYP11A1 promoter
confer NF-1C2 inhibition.
Endogenous CYP11A1 mRNA stability
Given our previously published observations of differences in
mRNA stability of CYP17A1 and GATA6 mRNAs in PCOS
theca cells [23,38], we also determined the stability (half-life) of
CYP11A1 mRNA in normal and PCOS theca cells. For these
studies, the decay of endogenous CYP11A1 mRNA over time was
examined under conditions where transcription was pharmaco-
logically blocked using the transcriptional inhibitor 5, 6-dichloro-
benzimidazole 1-ß-D-ribofuranoside (DRB) [23,39]. To induce
CYP11A1 mRNA, normal and PCOS theca cells were incubated
in serum-free media for 24 h, either in the absence or presence of
forskolin, prior to addition of 75 mM DRB. CYP11A1 mRNA
abundance was then measured by QRT-PCR analysis at various
time points (Fig. 5A) and the fraction of transcript remaining was
utilized to calculate the half-life of the CYP11A1 mRNA as
described in Materials and Methods. Half-life values for CYP11A1
mRNA were determined from 4 independent normal and 4
independent PCOS theca cell cultures and are presented in
Figure 5B. For normal theca cells, the decay of CYP11A1 mRNA
occurred with a half-life of 9.2261.62 h under basal conditions,
and 8.8061.33 h after forskolin treatment. In PCOS theca cells,
CYP11A1 mRNA decay occurred at a slower rate with a half-life
of 22.2860.95 h under basal conditions, and 24.0560.92 h in the
presence of forskolin treatment. The half-life of CYP11A1 mRNA
was extended by approximately 13–17 h in PCOS theca cells (a,
P,0.01) under both basal and forskolin-stimulated conditions.
Forskolin treatment, activation of adenylate cyclase, and increased
cAMP, did not significantly affect CYP11A1 mRNA half-life in
either normal or PCOS cells.
In vitro CYP11A1 mRNA decay and examination of the 59-
UTR of CYP11A1 mRNA
To further examine differences in CYP11A1 mRNA stability in
normal and PCOS theca cells, in vitro degradation assays were
performed as previously described in our laboratory [23]. In order
Figure 4. NF-1C2 regulation of the CYP11A1 promoter in theca
cells. A) The effect of human NF-1C2 on CYP11A1 promoter function
was examined in normal and PCOS theca cells transiently transfected
with the 21676 CYP11A1 luciferase construct and co-transfected with
an empty pcDNA plasmid, or a pcDNA plasmid expressing NF-1C2.
Following transfection, cells were cultured in transfection medium with
and without 20 mM forskolin (F) for 48 h. To determine the sequences in
the CYP11A1 promoter that confer NF-1C2 regulation, cells were
transfected with a B) pGL3 constructs containing 21676, 2160, or 290
to +49 bp of the 59-flanking sequence of the CYP11A1 gene, or C) the
minimal 2160/290 TK and empty TK constructs, following co-
transfection with pcDNA plasmid expressing NF-1C2 or an empty
pcDNA plasmid, the cells were cultured in serum free medium for 48 h.
All data are presented as relative luciferase (LUC) activity that was
normalized with b-galactosidase activity and represent the mean 6
SEM of multiple independent experiments. These experiments demon-
strate that NF-1C2 inhibits both basal (a, P,0.01) and forskolin (b,
P,0.01) stimulated 21676 CYP11A1 promoter function in normal and
PCOS theca cells, as well as basal 2160 CYP11A1 promoter function (a,
P,0.01) in PCOS theca cells. Moreover, sequences between 2160/
290 bp of the CYP11A1 promoter confer NF-1C2 inhibition.
doi:10.1371/journal.pone.0048963.g004
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to determine the region(s) of the CYP11A1 mRNA involved in
differential regulation of mRNA stability, in vitro degradation
assays were performed utilizing biotinylated CYP11A1 RNA
transcripts corresponding to the full length transcript, the coding
region alone, the 59-UTR+coding region, or the 39-UTR+coding
region (Fig. 6A). In these assays the biotinylated RNA transcripts
were incubated with cytoplasmic extracts prepared from normal
and PCOS theca cells that were grown until subconfluent then
placed in serum free medium for 24 h, as described in Materials
and Methods. In vitro half-lives of synthesized transcripts are
substantially shorter than endogenous half-lives, however, in vitro
degradation assays indicate rank orders of decay which reflects
relative differences in message stability among samples. As shown,
the half-life of the full-length CYP11A1 transcript was increased
.2-fold in PCOS extracts (a, P,0.01), as compared to normal
extracts (Fig. 5B). The half-life of the 59-UTR+coding transcript
was approximately 2-fold longer in PCOS extracts (b, P,0.01) as
compared to normal extracts (Fig. 6A). In contrast, the coding
transcript+39-UTR was markedly reduced in normal (*, P,0.01)
and PCOS (**, P,0.01) theca cells as compared to the
59UTR+coding transcript, and were similar in normal and PCOS
cells. The stability of the coding region alone was significantly
reduced as compared to full-length transcript and the 59UTR+-
coding transcript in PCOS cells (**, P,0.01), and was not
different in normal and PCOS. The stability of the b-actin
transcript was similar in normal and PCOS extracts [23]. These
data suggest that the 59-UTR alone, rather than the 39UTR or
coding regions of CYP11A1 mRNA contributes to increased
stability in PCOS. Furthermore, the 59-UTR is required for the
differential CYP11A1 mRNA stability observed in PCOS theca
cells.
To examine the extent to which the 59-UTR of CYP11A1
mRNA confers functional differences in reporter function in
PCOS theca cells, we transfected normal and PCOS theca cells
with a luciferase reporter construct containing the 59-UTR of
CYP11A1. As a control, replicate cultures of normal and PCOS
cells were transfected with a control pGL3 luciferase construct.
Following transfection the cells were treated with and without
20 mM forskolin for 48 hours. Experiments were performed in
triplicate in 4 different normal and PCOS patient’s cells. As shown
in Figure 6B, 59-UTR CYP11A1/LUC activity increased 2-fold in
PCOS theca cells (a, P,0.01) as compared to normal theca cells,
under both control and forskolin-stimulated conditions. Control
pGL3 LUC activity was not different in normal and PCOS theca
cells. These data suggest that the 59UTR of CYP11A1 mRNA
contributes to overall increased basal CYP11A1 gene expression in
PCOS theca cells.
Discussion
In this report long-term cultures of theca cells isolated and
propagated from normal cycling and PCOS women were utilized
to compare the regulation of CYP11A1 gene expression at the
transcriptional and post-transcriptional levels. CYP11A1 mRNA
accumulation was observed to be significantly increased, 3–4-fold,
in PCOS theca cells as compared to normal theca cells maintained
under basal or forskolin stimulated conditions (Fig. 1). Hence, in
PCOS theca cells, there is an underlying increase in basal, steady
state CYP11A1 mRNA accumulation, as compared to normal
theca cells, suggesting that basal CYP11A1 gene expression is
augmented in PCOS theca cells.
These studies represent the first examination of the promoter
elements involved in the regulation of CYP11A1 transcription in
human theca cells. Transient transfection analysis of theca cells
with reporter gene constructs containing successive serial deletions
of the 59 flanking region of CYP11A1 promoter demonstrated that
CYP11A1 promoter regulation was differentially regulated in
normal and PCOS cells (Fig. 2). More specifically, we observed
that CYP11A1 promoter function was increased PCOS theca cells.
Finer analysis of these deletion mutants in normal and PCOS
theca cells, demonstrated that a region of the CYP11A1 promoter
between 21676 to 2660 bp of the start site of transcription
conferred a 2–3 fold increase in cAMP-responsiveness (p,0.01) in
both normal and PCOS theca cells (Fig. 2). A minimal element,
between 2160 to 290 of the start site of transcription, conferred
increased basal regulation in PCOS theca cells when compared to
normal theca cells. In contrast, constructs containing 290 to
+45 bp of the CYP11A1 promoter, showed no basal or cAMP-
dependent regulation, and were not observed to be different in
normal and PCOS cells, or significantly different from transfection
of a control pGL3 plasmid (Fig. 2).
Figure 5. Endogenous CYP11A1 mRNA half-life in normal and
PCOS theca cells. The stability of endogenous CYP11A1 mRNA was
examined in normal and PCOS theca cells under untreated and forskolin
(20 mM)-stimulated conditions following treatment with the transcrip-
tional inhibitor DRB (75 mM) from 2–42 h. A) Graphical representation of
the amount of CYP11A1 mRNA remaining at each time interval,
determined by quantitative real-time PCR. B) The half-life of
endogenous CYP11A1 mRNA is presented as the mean 6 SEM from
independent examinations in 5 normal and 5 PCOS theca cell cultures.
CYP11A1 mRNA half-life was increased in PCOS theca, under both
untreated (a, P,0.01) and forskolin-stimulated conditions (a, P,0.01).
Forskolin treatment did not significantly alter CYP11A1 mRNA half-life in
normal or PCOS theca cells.
doi:10.1371/journal.pone.0048963.g005
Augmented CYP11A1 Expression in PCOS Theca Cells
PLOS ONE | www.plosone.org 8 November 2012 | Volume 7 | Issue 11 | e48963
Data demonstrating that serial deletion of sequences 59 of
21676 and 2660 bp of the CYP11A1 promoter ablated cAMP-
responsiveness further suggested that sequences in these regions
functionally acted like putative upstream cAMP (U-CRS) respon-
sive elements in theca cells (Fig. 2). These studies show strong
similarity to those examining cyclic AMP dependent regulation of
CYP11A1 transcription, and the U-CRS identified in adrenal Y1,
placental JEG and human granulosa cells [40]. The CYP11A1 U-
CRS cAMP-consensus element has been previously reported to
consist of a core SF-1 binding site (U element, TCAAGGTCA), at
21617/21609, and two flanking AP1/CBP sites (TGACTGAT),
at 21666/21626, and 21559/21553 [16,41,42]. Transient
transfection analysis of a the 21676D21540/290 CYP11A1
construct was performed to examine whether the U-CRS
conferred increased basal or cAMP regulation in normal and
PCOS theca cells (Fig. 3A–3B). Results of these studies showed
that the U-CRS, increased cAMP-dependent CYP11A1 to the
same extent in normal and PCOS theca cells, but did not confer
increased regulation in PCOS theca cells. These data confirm
those in the literature demonstrating that the U-CRS element
between 21640 to 21553 bp of the promoter confers basal and
cAMP-dependent regulation in both normal and PCOS theca
cells. In addition, demonstrating increased 21676D21540/290
promoter regulation compared to the full length 21676 CYP11A1
promoter construct, further provide evidence to suggest that
sequences between 21540 and 290 bp of the CYP11A1 promoter
confer differential regulation in normal and PCOS theca cells
(Fig. 3B).
In PCOS theca cells, significantly increased basal CYP11A1
promoter regulation was conferred by a 70 bp proximal regulatory
element located between 2160 and 290 bp of the transcriptional
start site. Examination of this nucleotide sequence revealed
putative consensus binding sites for several transcription factors,
including C/EBP-B, SF-1, COUP-TF, Trep-132, Sp-1, and NF-1.
Specific examination of the 2160/290 bp CYP11A1 minimal
element revealed sequence similarity to the bipartite recognition
sequence ((C/T)TGGC(N)6CC(N)3) for NF-1 [36,37]. NF-1C, also
referred to as CAAT-box transcription factor (CTF) [43], was the
first NF-1 family member identified and has been reported to
trans-activate and repress the transcription of a wide variety of
genes expressed in developmental and tissue-specific patterns [44–
47]. In human adrenal H295 cells, NF-1C was shown to bind the
CYP17A1 promoter, however functional studies were not reported
[24]. We recently reported that the NF-1 family member NF-1C2,
had the capacity to bind to and inhibit (i.e., repress) the CYP17A1
promoter in PCOS theca cells. Moreover, our studies revealed that
NF-1C2 protein levels in whole cell and nuclear extracts were
reduced in PCOS theca cells. Combined, these data demonstrated
that a reduction NF-1C2-dependent repression contributes to
increased CYP17A1 promoter activity and gene expression in
PCOS theca cells, thereby increasing androgen biosynthesis. In
view of the bipartite NF-1 consensus sequence in the minimal
2160/290 CYP11A1 promoter, and sequence similarities between
the minimal elements in the CYP17 and CYP11A1 promoters that
conferred increased basal regulation in PCOS cells, studies were
performed to investigate whether NF-1C2 coordinately regulates
(i.e., represses) the CYP11A1 minimal promoter. Results of
experiments examining the effects of co-transfection of NF-1C2
on a variety of CYP11A1 promoter constructs (Fig. 6A–6C),
showed that NF-1C2 had the capacity to inhibit luciferase activity
of the full length 21676/+45, or 2160/+45 and 2160/290TK
CYP11A1 promoter constructs. These data revealed that NF-1C2
had the capacity to repress CYP11A1 promoter function through
the 2160/290 bp element. In fact, deletion of the 2160/290
element that confers NF-1C2 regulation from the full length
21676 promoter construct, and is sufficient to convert the
augmented CYP11A1 promoter function observed in PCOS theca
cells to levels observed in normal theca cells (Fig. 3B). Hence, given
that NF-1C2 levels are reduced in PCOS theca cells, these data
suggest that a reduction in NF-1C2 repression results in increased
CYP11A1 promoter expression in PCOS theca cells. Furthermore,
they provide the first evidence to establish that NF-1C2
Figure 6. The 59UTR of CYP11A1 mRNA confers increased
stability in PCOS theca cells under basal conditions. A) The
individual half-lives of various CYP11A1 RNA probes were determined
using RNA in vitro degradation assays. Biotinylated CYP11A1 mRNA
transcripts (i.e., the full-length transcript, 59UTR+coding region, coding
region alone, and coding region +39UTR) were incubated with
cytoplasmic extracts isolated from either normal or PCOS theca cells.
The stability of each transcript over time (half-life) is presented as the
mean 6 SEM of five independent assays. The results of these
experiments demonstrated that the stability of CYP11A1 RNA
transcripts containing either the full-length (a, P,0.01) or 59+coding
region (b, P,0.01), were significantly increased in assays using PCOS
extracts, compared with normal extracts. The coding transcript+39-UTR
was markedly reduced in normal (*, P,0.01) and PCOS (**, P,0.01)
theca cells as compared to the 59UTR+coding transcript, and were
similar in normal and PCOS cells. B) To examine functional differences
in 59UTR of CYP11A1 in normal and PCOS theca cells, both cell types
were transiently transfected with a luciferase (LUC) construct containing
the 59 UTR of CYP11A1 mRNA and incubated in the absence (untreated)
or presence of forskolin (20 mM) for 48 h. Data are presented as relative
luciferase (LUC) activity following normalization by ß-galactosidase and
represent the mean 6 SEM from transfections performed in triplicate in
4 independent normal and 4 independent PCOS theca cells cultures.
Luciferase expression of the 59 UTR construct was significantly higher in
PCOS theca cells as compared to normal cells (a, P,0.05). Forskolin
treatment had no effect on CYP11A1 stability in normal or PCOS theca
cells.
doi:10.1371/journal.pone.0048963.g006
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coordinately regulates both CYP11A1 and CYP17 gene expression
in the PCOS ovary.
Numerous studies have established that the transcriptional
regulation of CYP11A1 gene expression involves specific transcrip-
tion factors and co-factors that bind and interact with the
CYP11A1 promoter is tissue- and species- specific manner.
However, to our knowledge there have been no studies that have
examined the post-transcriptional regulation of CYP11A1 gene
expression at the level of mRNA stability in any steroidogenic
tissue [41]. Gene expression profiles obtained from both steady
state and newly transcribed mRNA (measured in nuclear run on
studies) have revealed that the regulation of mRNA stability may
account for as much as 50% of all measurements of changes in
total cellular mRNA. Therefore, changes in the regulation of
mRNA stability in a disease state can have significant implications
on the up- or down- regulation of gene expression [48–50].
Regulation of mRNA turnover and stability is a major mechanism
for controlling gene expression involving the interaction of
cytoplasmic proteins, and in some cases microRNAs, that bind
to regulatory regions on the 59UTR, 39 UTR, and/or coding
regions of the mRNA [51]. In studies comparing normal and
PCOS theca cells, determination of endogenous CYP11A1
mRNA half-life by pharmacological inhibition of transcription
demonstrated that the half-life of CYP11A1 mRNA is increased
two-fold in PCOS theca cells, as compared to normal theca cells.
In vitro mRNA degradation studies and transient transfection of
59UTR CYP11A1 luciferase reporter constructs demonstrated
that the 59-UTR confers increased stability to CYP11A1 mRNA
in PCOS theca cells also approximately 2-fold under basal
conditions. These studies indicate that a slower rate of CYP11A1
mRNA decay contributes to increased steady state basal mRNA
accumulation and augmented CYP11A1 gene expression in PCOS
theca cells. In previous studies we also reported that CYP17A1
mRNA stability was increased in PCOS theca cells, under basal
and cAMP-dependent stimulation [23]. We also demonstrated a
similar requirement for the 59-UTR of CYP17A1, with the added
regulation of this 59-UTR by forskolin stimulation. The factors
that interact with the CYP17A1 or CYP11A1 mRNA are
unknown, and RNA binding site analyses of both 59-UTRs does
not suggest common binding by known RNA binding factors. It is
surprising that the 59-UTRs of both of these key steroidogenic
genes that are upregulated in PCOS are controlled by their 59-
UTRs. The majority of proteins that have been shown to regulate
mRNA stability bind to 39-UTRs. It is possible that the 59UTR of
CYP11A1 lacks cAMP-dependent regulation because it is only
44 bp, and is much smaller compared to the 212 bp 59-UTR of
CYP17A1. The regulation of steroidogenic enzyme expression by
modifications in RNA stability provides an added complexity and
level of regulation that will require further investigation to
determine the key factors and signaling pathways involved in
these processes. On the other hand, it is important to recognize
that the 44 bp 59-UTR confers a 2-fold increase in mRNA stability
in PCOS theca cells.
Compared to their normal counterparts, PCOS theca cells in
long-term culture produce increased amounts of steroids including
progestins, androgen precursors such as DHEA, and testosterone.
CYP11A1 gene expression, the rate-limiting step in steroid
biosynthesis is augmented in PCOS theca cells. This up-regulation
of steady state CYP11A1mRNA accumulation in PCOS theca cells
is associated with significant increases in both promoter activity
and transactivation of the CYP11A1 gene, and mRNA stability
through the 59-UTR of CYP11A1 mRNA.
In PCOS theca cells there is a coordinated increase in the
expression of several steroidogenic enzymes, including CYP17A1,
3ß-HSDII, Aldoketoreductase 1C2, (AKR1C1, encoding 20a-
HSD), and CYP11A1 [20]. This increase in steroidogenic enzyme
expression in PCOS theca cells is selective, and does not include all
of the enzymes involved in androgen and progestin biosynthesis,
such as StAR or 17ß-hydroxysteroid dehydrogenase type V (17ß-
HSDV) [20]. Both CYP17A1 [23] and CYP11A1 (Figs. 4–5)
mRNA transcription and stability are augmented under basal
conditions in PCOS theca cells. Also, the promoter elements
required for increased transcriptional activity of the two promoters
in PCOS theca cells map to sequences within 2180 bp of the start
site of transcription and contribute to significant basal regulation.
As for mRNA stability, both CYP11A1 and CYP17A1 transcripts
have greater that 2-fold longer half-life in PCOS theca cells.
Moreover, in vitro studies suggest that sequences within the 59-
UTRs of both mRNAs are mandatory for differential transcript
stability. Therefore, it seems likely that common regulatory
mechanism(s) and/or signaling pathways control both transcrip-
tion and mRNA stability of these transcripts, offering novel targets
for treatment of excess androgens in women with PCOS.
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